Register Free
Oncology Cardiology / Cardiovascular Respiratory / COPD / Asthma Infectious Disease Gastroenterology Diabetes / Metabolic Neurology Rheumatology Women's Health Mental Health / Psychiatry Dermatology Rare Diseases Men's Health
Trial Radar • ClinicalTrials.gov • Registry-linked

Trial Radar

1963 clinical trials with phase, status, specialty and registry links, summarised for rapid clinical review.

1963 recruiting AI clinical summaries
Explore Trial Collections Follow research updates
All Phases Phase I Phase II Phase III Phase IV
Therapeutic Area: All Cardiology / Cardiovascular Dermatology Diabetes / Metabolic Gastroenterology Haematology Infectious Disease Men's Health Mental Health / Psychiatry Nephrology Neurology Oncology Rare Diseases
🔬
Trial Radar

Clinical Trial Intelligence

● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Treatment being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated against a comparator treatment in patients with severe active GPA or MPA—rare…
20 May 2026 NCT06868290
● Recruiting Phase II Cardiology / Cardiovascular
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
What is being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated for efficacy and safety in treating severe active GPA (Granulomatosis with…
20 May 2026 NCT06868290
● Recruiting Cardiology / Cardiovascular
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
What is being tested: Creation of a high-resolution ECG data library paired with patient-reported insights to support future cardiovascular research and improve understanding of…
20 May 2026 NCT06809686
● Recruiting Cardiology / Cardiovascular
Study to Collect High-Resolution ECG Data and Patient Insights on Heart Failure Care
What is being tested: Collection of high-resolution ECG data and patient insights to build a comprehensive ECG library that will support future research into…
20 May 2026 NCT06809686
● Recruiting Cardiology / Cardiovascular
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
What is being tested: Convergent ablation (combining epicardial and endocardial approaches) plus left atrial appendage isolation using the LARIAT procedure, compared to standard endocardial…
20 May 2026 NCT06165510
● Recruiting Cardiology / Cardiovascular
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
What is being tested: Convergent ablation (combining epicardial and endocardial approaches) plus left atrial appendage isolation using the LARIAT procedure, compared to standard endocardial…
20 May 2026 NCT06165510
● Recruiting Cardiology / Cardiovascular
Monitoring Oedema in Heart Failure to Improve Function and Reduce Hospitalisation Risk
What is being tested: The Heartfelt device, a non-invasive 3D imaging system that passively monitors foot and lower leg volume to detect early fluid…
20 May 2026 NCT07067658
● Recruiting Phase III Oncology
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
Treatment being tested: Puxitatug samrotecan (AZD8205), a novel B7-H4-directed antibody-drug conjugate, compared against standard chemotherapy (doxorubicin or paclitaxel) in a Phase III randomized trial…
20 May 2026 NCT07044336
● Recruiting Phase III Oncology
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
What is being tested: Puxitatug samrotecan (AZD8205), a B7-H4-targeted therapy, versus standard chemotherapy (doxorubicin or paclitaxel) in patients with advanced/metastatic endometrial cancer that has…
20 May 2026 NCT07044336
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
What is being tested: Golcadomide combined with rituximab (Golca + R) versus standard investigator-selected treatment in patients with relapsed/refractory follicular lymphoma, evaluating efficacy and…
20 May 2026 NCT06911502
● Recruiting Phase III Oncology
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator’s Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Treatment being tested: Golcadomide combined with rituximab (Golca + R) versus investigator's choice treatment in patients with relapsed/refractory follicular lymphoma, evaluated in a Phase…
20 May 2026 NCT06911502
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
Intervention Being Tested: Radspherin® (a single intraperitoneal injection) is being evaluated as an adjunct to standard neoadjuvant chemotherapy and interval debulking surgery in patients…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
What is being tested: Radspherin® (a single intraperitoneal injection) is being evaluated for efficacy and safety in patients with primary advanced high-grade serous or…
20 May 2026 NCT06504147
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for efficacy and safety in managing cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
● Recruiting Phase II Oncology
Visugromab in Cachexia International Trial
What is being tested: Visugromab, a novel therapeutic agent, is being evaluated for safety and efficacy in treating cancer-associated cachexia (unintended weight loss) across…
20 May 2026 NCT07112196
● Recruiting Phase III Oncology
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
What is being tested: Surovatamig (AZD0486), a novel agent, combined with rituximab versus standard immunochemotherapy regimens (investigator's choice of 3 options) in treatment-naive follicular…
20 May 2026 NCT06549595
● Recruiting Phase III Oncology
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Treatment being tested: Surovatamig (AZD0486), a novel agent, combined with rituximab versus standard immunochemotherapy regimens (investigator's choice of three options) in previously untreated follicular…
20 May 2026 NCT06549595
active not recruiting Phase III
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
Atogepant tablets tested for treating individual migraine attacks in adults; currently approved only for prevention.
19 May 2026 NCT06241313
active not recruiting Phase II
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
Testing whether VHB937 drug slows early ALS progression compared to placebo over 40 weeks, then all patients receive active treatment.
19 May 2026 NCT06643481
● Recruiting Phase III Diabetes / Metabolic
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
Tirzepatide with lifestyle changes reduced weight and improved heart disease risk factors in obese teenagers with related health problems.
19 May 2026 NCT06439277
● Recruiting Phase III
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Trial testing atogepant tablets versus placebo for preventing chronic migraine in teenagers aged 12-17 years over 12 weeks.
19 May 2026 NCT06810505
● Recruiting Phase III Diabetes / Metabolic
AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss
AMAZE 12 Summary Trial testing whether weekly injections of NNC0487-0111 help people maintain weight loss compared to placebo.
19 May 2026 NCT07503210
active not recruiting Phase III Cardiology / Cardiovascular
Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)
Long-term safety and effectiveness study of inhaled seralutinib for pulmonary hypertension patients who previously completed earlier trials.
19 May 2026 NCT06274801
active not recruiting Phase III Oncology
A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies
Trial testing whether adding darolutamide to hormone therapy improves survival in men with early prostate cancer recurrence after surgery or radiotherapy.
19 May 2026 NCT05794906
active not recruiting Phase III Oncology
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
persevERA Trial Summary A new breast cancer drug (giredestrant) plus palbociclib compared to standard treatment (letrozole) plus palbociclib in advanced hormone-receptor-positive breast cancer.
19 May 2026 NCT04546009
● Recruiting Oncology
EVERiST: Impact of Image Detected Accessory Pudendal Artery on Erection Recovery After Nerve Sparing Prostatectomy
What is being tested: The EVERiST trial investigates whether pre-operative imaging detection of accessory pudendal arteries influences erectile function recovery following nerve-sparing radical prostatectomy…
19 May 2026 NCT07597798
● Recruiting Phase I Oncology
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Treatment being tested: Telisotuzumab adizutecan (an anti-HER3 antibody-drug conjugate) combined with a PD-1 immune checkpoint inhibitor in treatment-naïve advanced/metastatic non-squamous NSCLC without actionable genomic…
19 May 2026 NCT06772623
● Recruiting Phase III Rheumatology
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn’s Disease or Ulcerative Colitis (MK-7240-011)
What is being tested: Long-term safety and efficacy of tulisokibart (MK-7240), a novel therapeutic agent designed to treat active, moderate to severe Crohn's disease…
19 May 2026 NCT06651281
● Recruiting Phase III Respiratory / COPD / Asthma
A Study to Evaluate the Safety and Efficacy of CD388 for Prevention of Influenza
What is being tested: CD388 is a novel therapeutic agent administered as a single dose via 3 subcutaneous injections, being evaluated for its efficacy…
19 May 2026 NCT07159763
● Recruiting Cardiology / Cardiovascular
Exercise Prescription in Children With Hypertrophic Cardiomyopathy
What is being tested: The safety and efficacy of structured exercise prescription in children with hypertrophic cardiomyopathy (HCM), challenging the traditional conservative approach that…
19 May 2026 NCT07595354
● Recruiting Cardiology / Cardiovascular
Wearable Devices for Patient Monitoring in Long QT Syndrome
What is being tested: Utility of wearable devices for continuous patient monitoring in Long QT syndrome, a rare inherited cardiac arrhythmia disorder characterised by…
19 May 2026 NCT06887387
● Recruiting Cardiology / Cardiovascular
The Effect of Subclinical Leaflet Thrombosis and Prosthesis Type on Transcatheter Aortic Valve Degeneration (POPular PET TAVI)
What is being tested: The study investigates whether subclinical leaflet thrombosis detected on imaging predicts early bioprosthetic valve degeneration in TAVI patients at five…
19 May 2026 NCT05758662
● Recruiting Phase I Oncology
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
What is being tested: Etentamig (ABBV-383), an intravenously infused investigational agent, is being evaluated for safety and adverse events in adults with relapsed or…
19 May 2026 NCT05650632
● Recruiting Oncology
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
What is being tested: A non-invasive breath test that detects volatile organic compounds (VOCs) produced by pancreatic cancer cells, aiming to enable earlier detection…
19 May 2026 NCT07243262
● Recruiting Phase I Oncology
Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
What is being tested: AZD3632, an oral agent targeting HOX-overexpressing haematologic malignancies, is evaluated as monotherapy and in combination with anticancer agents, assessing safety,…
19 May 2026 NCT07155226
● Recruiting Phase III Oncology
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
What is being tested: Odronextamab, a novel bispecific antibody, is being evaluated for safety, tolerability, and efficacy compared to rituximab combined with chemotherapy in…
19 May 2026 NCT06091254
active not recruiting Phase II Respiratory / COPD / Asthma
Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)
A study testing a new drug (tulisokibart) to treat scleroderma patients with lung scarring to see if it's safe and effective.
18 May 2026 NCT05270668
● Recruiting Phase III
A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease
Emicizumab prophylaxis reduces bleeding events in Type 3 von Willebrand disease compared to standard on-demand treatment.
18 May 2026 NCT06998524
● Recruiting Oncology
A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy
Technology Being Tested: LaserSAFE confocal microscopy is being evaluated for its ability to accurately detect positive surgical margins (cancer cells at the edge of…
18 May 2026 NCT07541911
● Recruiting Phase II Oncology
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
What is being tested: A triplet combination therapy of inavolisib (PI3K inhibitor) added to ribociclib (CDK4/6 inhibitor) and fulvestrant (endocrine therapy) compared to standard…
18 May 2026 NCT07405801
● Recruiting Mental Health / Psychiatry
Effect of a Food Intervention With a Prebiotic Alone or Combined With B-vitamins on Gut Microbiota Diversity, Inflammation and Mental Health Outcomes in Older Adults (GutFood)
What is being tested: A food-based intervention containing prebiotics (alone or combined with B-vitamins) to evaluate effects on gut microbiota diversity, systemic inflammation markers,…
18 May 2026 NCT07592975
● Recruiting Phase III Cardiology / Cardiovascular
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
What is being tested: Sotagliflozin (a dual SGLT1/SGLT2 inhibitor) efficacy and safety in reducing symptoms and functional limitations in patients with symptomatic hypertrophic cardiomyopathy,…
18 May 2026 NCT06481891
● Recruiting Phase III Oncology
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Treatment being tested: Nemtabrutinib (a Bruton's tyrosine kinase inhibitor) combined with venetoclax compared to the standard regimen of venetoclax plus rituximab in patients with…
18 May 2026 NCT05947851
active not recruiting Phase III
Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)
Povetacicept reduced proteinuria and slowed kidney decline in adults with IgA nephropathy compared to placebo.
15 May 2026 NCT06564142
● Recruiting Phase III
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
TIGER Trial Summary Surgery plus anti-VEGF injections versus anti-VEGF alone for bleeding under the macula in wet age-related macular degeneration.
15 May 2026 NCT04663750
active not recruiting Phase II Oncology
Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM)
Nivolumab showed activity and tolerable side-effects in previously-treated thymic carcinoma and B3 thymoma patients.
15 May 2026 NCT03134118
● Recruiting Phase III
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Trial testing sodium zirconium cyclosilicate to treat high potassium levels in children aged under 18 years across correction, maintenance and long-term phases.
15 May 2026 NCT03813407
active not recruiting Phase III
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Gene therapy NTLA-2002 reduced hereditary angioedema attacks more effectively than placebo in a Phase 3 trial.
15 May 2026 NCT06634420
active not recruiting Phase I Oncology
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Trial of new hormone therapy GDC-9545 alone or combined with existing drugs for advanced oestrogen receptor-positive breast cancer.
15 May 2026 NCT03332797
active not recruiting
Long-term Effectiveness, Safety, and Performance of the Evoke Closed-Loop SCS System to Treat Patients With Chronic Pain of the Trunk and/or Limbs
Closed-loop spinal cord stimulation (Evoke system) safely and effectively reduces chronic trunk and limb pain long-term in real-world patients.
15 May 2026 NCT04627974